LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fireside Chat with Theranos Whistleblowers

By AACC
Posted on 12 Jul 2022
Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Tuesday, July 26
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center


Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.

After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.

Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.

Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more